Lactate Biomarker May Predict Outcomes in Cardiogenic Shock - Summary - MDSpire

Lactate Biomarker May Predict Outcomes in Cardiogenic Shock

  • By

  • Andrea Surnit

  • June 23, 2026

  • 4 min

Share

Objective:

To synthesize evidence on the pathophysiology, prognostic value, and clinical interpretation of serum lactate in patients with cardiogenic shock.

Approach:
  • Evidence Review: Investigators reviewed clinical trials, registries, observational studies, and studies involving temporary mechanical circulatory support.
Key Findings:
  • Admission lactate is associated with shock severity and mortality.
  • Lactate thresholds of approximately 3 to 3.5 mmol/L indicate higher risk of short-term mortality.
  • A baseline lactate level of 5 mmol/L predicts 30-day mortality in acute myocardial infarction-related cardiogenic shock.
  • Serial lactate monitoring reflects metabolic recovery and response to therapy.
  • Lactate measured 8 hours after presentation predicts 30-day mortality more accurately than baseline lactate.
  • Reductions in lactate during the first 12 to 24 hours are associated with improved survival.
  • Complete lactate clearance is a strong predictor of survival.
  • Persistent hyperlactatemia despite adequate device flow indicates poor outcomes.
Interpretation:

Lactate levels reflect disease severity and should be interpreted in the context of clinical conditions, not as standalone measures.

Limitations:
  • The review is a narrative synthesis of heterogeneous sources.
  • Lactate values should be interpreted within the broader clinical context.
Conclusion:

Trajectory-based lactate assessment may provide important information for risk stratification and therapeutic guidance.

Sources:

Original Source(s)

Related Content